Curosurf

Curosurf (Poractant Alfa) is a natural surfactant used for respiratory support in premature infants. This product helps improve lung function and reduce respiratory distress syndrome (RDS).

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. It works by replacing the natural surfactant in the lungs, which helps the lungs expand more easily. This medication is administered via endotracheal tube directly into the lungs. Curosurf is often used in neonatal intensive care units (NICUs) to support breathing in premature babies who have difficulty breathing due to underdeveloped lungs.

Curosurf helps to improve lung function by reducing the surface tension in the alveoli, allowing the lungs to expand more easily. This can lead to improved oxygenation and reduced need for mechanical ventilation. The effects of Curosurf are typically observed shortly after administration, providing immediate respiratory support.

Curosurf should be administered by healthcare professionals experienced in neonatal care. It is important to follow proper handling and storage guidelines to maintain the efficacy of the medication. Always consult a healthcare provider for specific instructions and precautions related to the use of Curosurf.

Curosurf is generally well-tolerated, but it is important to inform your healthcare provider about any other medications or treatments your infant is receiving. Certain medications or medical conditions may interact with Curosurf, so it is crucial to discuss all aspects of your infant's health with a healthcare professional.